Cellectra™ Human CD8 NanoSort Microbeads, Research grade

This product is compatible with mainstream automated cell processing instruments and commercially available column-based (M/D/L) magnetic separation systems.

Superior Cell Separation Performance Separation performance was evaluated using samples containing 1×10⁷ human PBMCs, processed with CD8 microbeads from Acro, Company M, or Company T at recommended dosages. Positive and negative fractions were collected, and 1×10⁶ cells from each fraction were immunostained with PE-conjugated anti-human CD8 antibody and 7-AAD, followed by flow cytometric analysis. Data indicated that Acro microbeads achieved a final purity of 98% (baseline: 27.15%), with a target cell residue of only 1.69% in the negative fraction. These findings validate outstanding separation performance, confirming an optimal balance of purity and recovery relative to Company M benchmarks.

Comparison of Cell Separation Performances Isolation efficacy was validated using samples containing 1×10⁷ human PBMCs processed with the recommended dosage of Cellectra™ Human CD8 NanoSort Microbeads, in parallel with product from Company M and Company T. Comparative analysis demonstrated that Acro NanoSort Microbeads achieved higher cell recovery rates than Company M/T, while purity and cell viability were comparable to Company M and superior to Company T.

Cell Separation Performances of Different Donors The separation performances of human PBMCs exhibited minor inter-donor variability, yet consistently maintained high purity and cell recovery across all donors (Routinely tested).

Cell Separation Performances after Freeze-Thawing and Accelerated Aging at 37℃ Freeze-thaw stability was verified by subjecting the microbeads to 2–3 cycles prior to separation testing. Comparative analysis against the standard batch confirmed that purity and cell recovery were maintained at baseline specifications, demonstrating robust stability. To ensure prolonged shelf life, storage at -20°C or below is recommended upon receipt (however, repeated freeze-thaw cycles are not advised for routine operational use). Accelerated aging studies were conducted at 37°C to evaluate long-term stability profiles. Following 7 and 14-day incubation periods, the microbeads sustained high purity and cell recovery performance during PBMC separation. These data substantiate product stability and validate the established shelf-life specifications.

Batch-to-Batch Consistency Manufacturing reproducibility was verified by conjugating three batches of CD8 NanoSort Microbeads with three corresponding batches of synthesized magnetic beads. Performance testing for human PBMC separation was conducted without dose adjustment; final dosage optimization will be completed during the pre-launch phase. Data indicates that all batches achieved consistent high purity and recovery, establishing reliable batch-to-batch consistency.